Actelion Share Price Xetra

Stocks

31/17/31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/17/19	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/17/09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/17/22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/17/18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/17/20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/17/18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/17/05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/17/31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/17/23	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/20/06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/17/30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/17/16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/17/16	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/18/29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/18/29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/18/22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/17/31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/17/30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	+2.35%	+0.77%	+29.92%	+85.38%	5.52TCr
ARGENX SE	-0.21%	-7.38%	+25.34%	+63.02%	5.38TCr
BIONTECH SE	-1.99%	+1.67%	-15.52%	-16.58%	2.35TCr
INSMED INCORPORATED	-3.85%	-8.64%	-8.94%	+342.21%	2.2TCr
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-1.27%	+15.99%	-10.53%	1.98TCr
GENMAB A/S	+0.79%	-1.06%	+29.29%	-33.32%	1.74TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-7.23%	+24.50%	+519.07%	1.47TCr
EXELIXIS, INC.	-4.60%	-3.76%	+47.13%	+170.37%	1.41TCr
PHARMAESSENTIA CORPORATION	+3.41%	-7.83%	+161.76%	+284.91%	1.3TCr
Average	-0.12%	-1.43%	+34.38%	+156.06%	2.59TCr
Weighted average by Cap.	+0.15%	+0.09%	+27.45%	+120.67%